We appreciate the opportunity to respond to the letter from Dr. Inès Harzallah et al. I have also performed antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin, and anti–β2‐glycoprotein I in dozens of our patients; however, very few of them got positive results. We do not believe that antiphospholipid antibody exists universally in COVID‐19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter1 also seem to meet the International Society on Haemostasis and Thrombosis criteria of disseminated intravascular coagulation,2 the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain.
Both the International Society on Haemostasis and Thrombosis and the Clinical and Laboratory Standards Institute guidelines have urged caution when interpreting LAC results in patients receiving anticoagulants.3., 4. Given common use of low molecular weight heparin and unfractionated heparin for thromboprophylaxis in COVID‐19 inpatients, false‐positive results resulting from interference of these anticoagulants may be an important reason for the high positive rate of LAC mentioned in this letter. It has been recommended that the blood should be drawn for LAC testing after 12 hours since the last dose of low molecular weight heparin and 24 hours since that of rivaroxaban.3., 5.
CONFLICT OF INTEREST
None declared.
Footnotes
Manuscript handled by: David Lillicrap
Final decision: David Lillicrap, 02 May 2020
REFERENCES
- 1.Zhang Y., Xiao M., Zhang S., et al. Coagulopathy and antiphospholipid antibodies in patients with Covid‐19. N Engl J Med. 2020;382(17):e38. doi: 10.1056/NEJMc2007575. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Taylor F.B., Jr, Toh C.H., Hoots W.K., et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–1330. [PubMed] [Google Scholar]
- 3.Pengo V., Tripodi A., Reber G., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7(10):1737–1740. doi: 10.1111/j.1538-7836.2009.03555.x. [DOI] [PubMed] [Google Scholar]
- 4.Ledford‐Kraemer M.M.G., Bottenus R., Brandt J.T., et al . Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60‐A. Clinical and Laboratory Standards Institute; Wayne, PA: 2014. [Google Scholar]
- 5.Góralczyk T., Iwaniec T., Wypasek E., Undas A. False‐positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul Fibrinolysis. 2015;26(4):473–475. doi: 10.1097/MBC.0000000000000235. [DOI] [PubMed] [Google Scholar]